In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...

Job Title Sort ascending Business Location Site Date Posted Medical Affairs Lead Regolare, Full time Germany +Alternative Locations Munich (Non-Sales Force) (Novartis Pharma GmbH) Apr 11, 2025 ...

Munich (Non-Sales Force) (Novartis Pharma GmbH) Apr 11, 2025 Medical Affairs Lead Regular, Full time Germany +Alternative Locations Munich (Non-Sales Force) (Novartis Pharma GmbH) Apr 11, 2025 Start ...